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Diversity, evolution, and epidemiology ofHIV are directly relevant toHIV transmission andpathogenesis; hence, they play a key role
in antiretroviral treatment and vaccine design.GlobalHIVwhole-genome sequencingwould provide a treasure chest of data to answer
many questions still open in these fields. An article by Berg et al. in this issue of the Journal of ClinicalMicrobiology describes a univer-
sal strategy to amplify and sequence heterogeneousHIVwhole genomes (M.G. Berg, J. Yamaguchi, E. Alessandri-Gradt, R.W. Tell,
J.-C. Plantier, andC. A. Brennan, J ClinMicrobiol 54:868–882, 2016, http://dx.doi.org/10.1128/JCM.02479-15).
Human immunodeficiency virus (HIV), the cause of pandemicAIDS, is one of—if not the most—extensively investigated
viruses. Numerous breakthroughs that have benefits beyond the
field of virology were made in HIV research. The most notable,
perhaps, is the unprecedented achievement of transforming a
deadly infection into a chronic disease by the introduction of
combination antiretroviral therapy. But why have previous at-
tempts to develop an effective vaccine been unsuccessful? Because
HIV is a master of evolution. As a rapidly replicating RNA virus
with a small genome size (10 kb) and a high mutation rate, all
possible single-point mutations could arise in an untreated HIV-
infected individual daily.Withmore than 37millionHIV-infected
individuals worldwide today, HIV is one of the world’s most ge-
netically diverse pathogens. Currently, two types of HIV exist:
HIV-1 and HIV-2. HIV-1 is the cause of the pandemic and is
divided into four groups that, on average, feature 37.5% diversity
among each other. The main group, M, is further subdivided into
nine subtypes and numerous circulating recombinant forms. On
average, the percentages of genome diversity among and within
HIV-1 subtypes are 14.7% and 8.2%, respectively, whereas much
higher diversity can be observed in certain variable regions such as
env (1). Thus, global molecular surveillance is a necessity to mon-
itor dynamics of HIV diversity and to identify newly emerging
HIV strains that may have an impact on diagnostic assay designs
and antiretroviral therapy efficacy.
The rapid development of next-generation sequencing (NGS)
technology for the past decade could not have come at a better
time.Within a fewdays, billions of sequence reads can be obtained
at decreasing costs, and experimental procedures applying NGS
technologies are constantly becoming easier. Three years ago, the
first pan-HIV-1 strategy to amplify HIV whole genomes using
primers in semiconserved regions of all HIV-1 groups and sub-
types and sequenced with NGS was published (2). In this issue of
Journal of Clinical Microbiology, another pan-HIV strategy is de-
scribed by Berg et al. (3): a more universal approach applying the
SMART (switchingmechanism at 5= end of RNA transcript) tech-
nology. Here, multiple adaptor-tagged pan-HIV primers are used
for reverse transcription of viral RNA into cDNA followed by the
addition of nucleotides at the 5= end of the cDNA. To this exten-
sion, another adaptor-tagged primer is hybridized, leading to the
switch of template by the reverse transcriptase and the replication
of the adaptor. The final cDNA can then be amplified using adap-
tor-specific primers. This approach captures a higher diversity of
genetic variants, albeit with lower sensitivity,meaning higher viral
loads are required to successfully obtain HIV whole-genome se-
quences compared to HIV-specific amplification procedures (3).
In lockstep with the continuing evolution of NGS technologies
and experimental procedures, the bioinformatics community has
developed many computational tools capable of keeping up with
the increasing amount of data and instrumental in their interpre-
tation. However, experimental and computational challenges re-
main (4), and with the accumulation of sequence data, more so-
phisticated computer software and infrastructure as well as
continuing close collaborations among experimental, clinical, and
computational scientists are required.
Nevertheless, NGS technologies enable unprecedented oppor-
tunities to investigate HIV diversity. Global molecular surveil-
lance to identify newly emerging HIV strains is only one of nu-
merous possible applications. Large-scale HIV-1 whole-genome
sequencing will provide more detailed insights into viral evolu-
tionary processes among and within hosts, infection clusters and
transmission chains, fitness landscapes of virus populations, and
pathogenesis of different subtypes—to name a few.
New NGS technologies are not only used in science; they are
also entering diagnostic laboratories. BenchtopNGSmachines are
progressively replacing Sanger sequencers since on top of gener-
ating consensus sequences, they also have the ability to (ultra-)
deep sequence, which is essential in the detection and quantifica-
tion of low-abundance viruses such as minority drug-resistant
HIV variants (5). Although the clinical impact of minority drug-
resistant HIV variants remains unclear (6), large-scale and deep
HIV genome sequencing could provide the data needed to define,
for instance, clinically relevant cutoffs for drug resistance muta-
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tions. This information, however, cannot be inferred from HIV
sequences alone. Clinical data from well-characterized HIV-in-
fected individuals are equally important.
A word of caution should be added with respect to the imple-
mentation of these new NGS technologies in routine diagnostic
settings. Besides a robust laboratory procedure to amplify and
sequence a broad range of heterogeneous HIV strains, other re-
quirements have to be fulfilled. Cost-effectiveness, high accuracy
and sensitivity, reproducibility, and standardized analysis are cru-
cial considerations for a clinical pipeline to be practical. The cost
for routine HIV drug resistance testing might remain the same
using Sanger or NGS sequencers, particularly in laboratories with
high sample throughputs. Accuracy, sensitivity, and reproducibil-
ity in calling consensus sequences and detecting majority drug
resistancemutations are noninferior to population sequencing (5,
7, 8). Similarly, standardized analysis and routinely used interpre-
tation algorithms (e.g., the Stanford HIV Drug Resistance Data-
base and geno2pheno) are applicable to Sanger sequencing- or
NGS-derived consensus sequences. For these reasons, the applica-
tion of new NGS methodologies in diagnostic settings should not
pose a remarkable challenge as long as the analysis involves con-
sensus sequences only. However, detection and quantification of
minority HIV variants are much more difficult and remain com-
plex (4). Numerous experimental procedures and analysis pipe-
lines for differentNGS platforms have been developedworldwide,
highlighting the efforts undertaken to further explore HIV diver-
sity. As most of these protocols differ in terms of primer design,
amplification and sequencing conditions, and data analysis, it is
high time to conduct interlaboratory studies in order to consoli-
date both experience and knowledge (7, 9).
In summary, the application of NGS technologies for HIV
whole-genome sequencing will provide unprecedented insights
into genomic structures of virus populations that may be directly
relevant for clinical and scientific topics, such as personalized an-
tiretroviral treatment and vaccine design. The global monitoring
of HIV diversity is important for the surveillance of the pandemic
and could have immediate consequences for antiretroviral treat-
ment and diagnostic assay designs. In the long run, these data
might even aid in the prediction of virus evolution, such as path-
ways of HIV to escape immune and drug pressures in HIV-in-
fected individuals. Together with clinical and epidemiological
data and host genomic information, HIV whole-genome se-
quences will allow insights into the highly complex host-pathogen
interactions. It is undoubtedly a golden age for research in virus
evolution and epidemiology.
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